Suppr超能文献

外周型苯二氮䓬受体水平与人类乳腺癌MDA - MB - 231细胞系在严重联合免疫缺陷(SCID)小鼠体内生长的能力相关。

Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice.

作者信息

Hardwick M, Rone J, Han Z, Haddad B, Papadopoulos V

机构信息

Division of Hormone Research, Department of Cell Biology, Georgetown University Medical Center, Washington, DC 20007, USA.

出版信息

Int J Cancer. 2001 Nov 1;94(3):322-7. doi: 10.1002/ijc.1472.

Abstract

MDA-MB-231 (MDA-231) human breast cancer cells have a high proliferation rate, lack the estrogen receptor, express the intermediate filament vimentin, the hyaluronan receptor CD44, and are able to form tumors in nude mice. The MDA-231 cell line has been used in our laboratory to examine the role of the peripheral-type benzodiazepine receptor (PBR) in the progression of cancer. During these studies 2 populations of MDA-231 cells were subcloned based on the levels of PBR. The subclones proliferated at approximately the same rate, lacked the estrogen receptor, expressed vimentin and CD44, and had the same in vitro chemoinvasive and chemotactic potential. Both restriction fragment length polymorphism and comparative genomic hybridization analyses of genomic DNA from these cells indicated that both subclones are of the same genetic lineage. Only the subclone with high PBR levels, however, was able to form tumors when injected in SCID mice. These data suggest that the ability of MDA-231 cells to form tumors in vivo may depend on the amount of PBR present in the cells.

摘要

MDA-MB-231(MDA-231)人乳腺癌细胞增殖率高,缺乏雌激素受体,表达中间丝波形蛋白、透明质酸受体CD44,且能够在裸鼠体内形成肿瘤。在我们实验室中,MDA-231细胞系已被用于研究外周型苯二氮䓬受体(PBR)在癌症进展中的作用。在这些研究过程中,根据PBR水平对MDA-231细胞进行了亚克隆,得到了两个亚克隆群体。这些亚克隆的增殖速率大致相同,缺乏雌激素受体,表达波形蛋白和CD44,并且具有相同的体外化学侵袭和趋化潜能。对这些细胞的基因组DNA进行的限制性片段长度多态性分析和比较基因组杂交分析均表明,这两个亚克隆属于同一遗传谱系。然而,只有PBR水平高的亚克隆在注射到SCID小鼠体内时能够形成肿瘤。这些数据表明,MDA-231细胞在体内形成肿瘤的能力可能取决于细胞中PBR的含量。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验